Nicox launches commercial operations in Germany

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced the launch of its German operations. Nicox is now promoting and selling Xailin(TM), a new range of tear lubricants for relief of dry eye symptoms (medical devices), and AdenoPlus®, an in vitro diagnostic medical device (IVDMD) to help the differential diagnosis of acute conjunctivitis, through its own sales force in Germany.

In line with its strategy, Nicox has been establishing its own commercial infrastructure in the United States and the five largest European markets. The first Xailin(TM) products, as well as AdenoPlus®, were launched in the UK, Italy, Spain and France in March 2014. In Germany, Nicox appointed Torsten Cornelius as Country Manager in April 2014, to recruit and lead the Group's German sales force. Overall, the European commercial team had 99 employees at the end of June 2014.

Torsten Cornelius brings over 17 years of commercial and market development experience in the pharmaceutical industry, mainly with Alcon, Pfizer and Biogen Idec. He held different commercial positions in different therapeutic areas including ophthalmology and brings significant experience in Sales Force Management.

...................................

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is latanoprostene bunod, a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com.

...................................

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2013 » filed with the French Autorité des Marchés Financiers (AMF) on April 2, 2014 and available on Nicox's website (www.nicox.com) and on the AMF's website (www.amf-france.org).

...................................

Contacts

Nicox	Gavin Spencer \| Executive Vice President Corporate Development
	Tel +33 (0)4 97 24 53 00 \| communications@nicox.com

Media Relations

United Kingdom	Jonathan Birt
	M +44 7860 361 746 \| jonathan.birt@ymail.com

France	Caroline Courme \| Communication Manager
	Tel +33 (0)4 97 24 53 43 \| courme@nicox.com